Cover Image
市場調查報告書

絲裂原(分裂促進因子)活性化蛋白激酶1:開發中產品分析

Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 365754
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
絲裂原(分裂促進因子)活性化蛋白激酶1:開發中產品分析 Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Pipeline Review, H1 2018
出版日期: 2018年02月27日 內容資訊: 英文 51 Pages
簡介

本報告提供以絲裂原(分裂促進因子)活性化蛋白激酶1為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

絲裂原(分裂促進因子)活性化蛋白激酶1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Aeterna Zentaris Inc.
  • AGV Discovery, SAS
  • Asana BioSciences, LLC
  • Genentech, Inc.
  • Kura Oncology, Inc.
  • Laurent Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Merck KGaA

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1320TDB

Summary:

According to the recently published report 'Mitogen Activated Protein Kinase 1 - Pipeline Review, H1 2018'; Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies.

Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Mitogen-activated protein kinase 14 also called p38-alpha is an enzyme belongs to p38 MAPK family. p38-alpha MAPK play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. p38-alpha MAPK is expressed in many cell types. p38-alpha MAPK is implicated in cell apoptosis, proliferation, differentiation, migration, mRNA stability, and inflammatory response in different cell types through variety of different target molecules.

The report 'Mitogen Activated Protein Kinase 1 - Pipeline Review, H1 2018' outlays comprehensive information on the Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 1 and 4 respectively. Report covers products from therapy areas Oncology and Musculoskeletal Disorders which include indications Colorectal Cancer, Non-Small Cell Lung Cancer, Metastatic Melanoma, Pancreatic Ductal Adenocarcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colon Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Myelodysplastic Syndrome, Osteoarthritis, Pancreatic Cancer, Solid Tumor and Uveal Melanoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24)
  • The report reviews Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Overview
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Companies Involved in Therapeutics Development
  • Aeterna Zentaris Inc
  • AGV Discovery SAS
  • Asana BioSciences LLC
  • Eli Lilly and Co
  • Kalyra Pharmaceuticals Inc
  • Kura Oncology Inc
  • Merck & Co Inc
  • Merck KGaA
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Drug Profiles
  • ASN-007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CB-745 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JRP-890 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KO-947 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-3214996 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MK-8353 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Aurora B Kinase and ERK2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ERK1 and ERK2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ERK1 and ERK2 for Pancreatic Ductal Adenocarcinoma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sprifermin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ulixertinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Dormant Products
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Discontinued Products
  • Mitogen Activated Protein Kinase 1 (ERT1 or MAP Kinase Isoform p42 or Extracellular Signal Regulated Kinase 2 or Mitogen Activated Protein Kinase 2 or MAPK1 or EC 2.7.11.24) - Product Development Milestones
  • Featured News & Press Releases
  • Jan 03, 2018: Asana BioSciences Announces Acceptance of IND Application for Its Oral ERK1/2 Inhibitor
  • Dec 15, 2017: First-in-class ERK1/2 Inhibitor Safe, Shows Early Efficacy in Patients With Advanced Solid Tumors
  • Nov 04, 2017: Merck KGaA, Darmstadt, Germany Presents Late Breaking Clinical Data from Phase II Trial of Sprifermin for Osteoarthritis Disease Modification
  • Oct 24, 2017: Asana BioSciences to Present Update On Lead Molecule ASN-007 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  • Oct 20, 2017: Merck Presents New Data on Sprifermin at 2017 ACR/ARHP Annual Meeting
  • Oct 03, 2017: First-in-class ERK inhibitor ulixertinib (BVD-523) shows promise in preclinical cancer models
  • Jun 21, 2017: NovellusDx Announced the Completion of the First Phase of an In-vitro Study of BioMed Valley Discoveries' BVD523
  • May 26, 2017: BioMed Valley Discoveries announces presentation of early clinical activity of first-in-class cancer therapy ulixertinib at 2017 ASCO annual meeting
  • Apr 19, 2017: Kura Oncology Granted U.S. Patent for Clinical-Stage ERK Inhibitor, KO-947
  • Apr 07, 2017: Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947
  • Apr 05, 2017: Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947
  • Mar 29, 2017: Kura Oncology to Present Preclinical Data on KO-947 at AACR Annual Meeting 2017
  • Jan 04, 2017: Kura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947
  • Dec 01, 2016: Kura Oncology Presents Preclinical Data on KO-947 the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • Nov 15, 2016: Kura Oncology to Present Preclinical Data on Pipeline Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Aeterna Zentaris Inc, H1 2018
  • Pipeline by AGV Discovery SAS, H1 2018
  • Pipeline by Asana BioSciences LLC, H1 2018
  • Pipeline by Eli Lilly and Co, H1 2018
  • Pipeline by Kalyra Pharmaceuticals Inc, H1 2018
  • Pipeline by Kura Oncology Inc, H1 2018
  • Pipeline by Merck & Co Inc, H1 2018
  • Pipeline by Merck KGaA, H1 2018
  • Dormant Projects, H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top